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Alterations in DNA methylation are seen in cancers and have also been examined in clear cell renal cell carcinoma
(ccRCC). Numerous tumor suppressor genes have been reported to be partially or completely silenced due to
hypermethylation of their promoters in single-locus studies, and the use of hypomethylating agents has been
shown to restore the expression of many of these genes in vitro. In particular, members of the Wnt and TGF-beta
pathways, pro-apoptotic genes such as APAF-1 and negative cell-cycle regulators such as KILLIN have been shown
to be epigenetically silenced in numerous studies in ccRCC. Recently, TCGA analysis of a large cohort of ccRCC
samples demonstrated that aberrant hypermethylation correlated with the stage and grade in kidney cancer. Our
genome-wide studies also revealed aberrant widespread hypermethylation that affected regulatory regions of the
kidney genome in ccRCC. We also observed that aberrant enhancer hypermethylation was predictive of adverse
prognosis in ccRCC. Recent discovery of mutations affecting epigenetic regulators reinforces the importance of
these changes in the pathophysiology of ccRCC and points to the potential of epigenetic modulators in the
treatment of this malignancy.
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Renal cell carcinoma (RCC) is the most common ma-
lignant neoplasm arising in the kidney. These cancers
encompass a heterogeneous group of tumors and are
classified on the basis of morphology and histology into
clear cell carcinomas (60 % of cases), papillary tumors,
chromophobic tumors, oncocytomas, and collecting or
Bellini duct tumors. The number of cases of RCC con-
tinues to rise annually and is usually more common in
males (2:1) with peak incidence between 50–70 years of
age. RCC is usually sporadic, but some familial forms
have been reported like the one associated with von
Hippel-Lindau (VHL) syndrome.
Epigenetics is the study of heritable changes in gene
expression without alteration of the DNA sequence.
Epigenetic changes could involve chemical modification
of DNA bases via methylation of cytosines, or histone
protein modification, or regulation by non-coding RNAs.
DNA methylation involves the addition of a methyl group
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common reversible epigenetic alteration that has been re-
ported in many cancers. Methylation is facilitated by DNA
methyltransferase (DNMT) enzymes. Hypermethylation of
promoter or enhancer CpG regions can result in inactiva-
tion of important tumor suppressor genes whereas hypo-
methylation of genomic DNA has been associated with
chromosomal instability and tumorigenesis. The role of
DNA methylation in RCC has been an active area of re-
search over the past decade, and the various genes that
are epigenetically altered in this cancer by DNA methy-
lation have been reviewed here to give us an insight
into the numerous pathways that can be influenced by
hypomethylating agents.SFRP1 gene
It is a tumor suppressor gene encoding secreted frizzled-
related protein 1 (SFRP1), a WnT antagonist controlling
cell growth and neovascularization. Epigenetic silencing
of SFRP1 gene occurs in premalignant tissues associated
with chronic inflammation or in human cancer [1]. The
tumorigenic role of SFRP1 in RCC cell lines has been
demonstrated by functional analyses [2]. The evaluation
of the methylation status of SFRP1 gene in clear cellrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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methylation-specific PCR (MSP) revealed hypermethyla-
tion in 8 of 10 tumor samples and 1 of 10 normal samples.
Four ccRCC cell lines A498, 786-O, UMRC3, and ACHN
revealed CGI methylation providing additional evidence of
the role of methylation in the loss of SFRP1 expression in
ccRCC [3].
Rap1GAP gene
It encodes for Rap1Gap protein that inactivates Rap,
which is a protein involved in cancer growth, invasion,
and metastasis [4]. Rap1GAP protein is a member of the
Rap GTPase-activating protein (GAP) family, which has
been documented to regulate integrin-mediated cell
adhesion pathways [5]. Rap1Gap promoter was found
to be hypermethylated in RCC cell lines—SN12C and
Caki-1—and treatment with decitabine (5-aza-2′-deox-
ycytidine) of SN12C cells significantly increased the
relative expression of Rap1Gap. Treatment with decita-
bine restoring the expression of Rap1GAP showed a
significant reduction in the invasiveness of SN12C and
Caki1 of matrigel matrices, suggesting a role in cancer
cell invasion. However, Rap1Gap was shown to have no
impact on cancer cell proliferation in either of the two
cell lines [6].
KILLIN gene
KILLIN gene is involved in cell-cycle arrest and is regu-
lated by p53. It encodes for a small nuclear DNA-
binding protein that inhibits DNA synthesis in vitro and
causes the S-phase arrest [7]. In a study conducted to
determine the methylation and expression of KILLIN in
germline, somatic, and RCC cell lines, 23 out of 41
ccRCC patients (56 %) exhibited germline methylation
of KILLIN promoter whereas none of the 50 controls
showed methylation (p < 0.0001). Somatic hypermethyla-
tion examined in 19 primary ccRCC tumor specimens
and 1 metastatic RCC specimen revealed that 19 (95 %)
had hypermethylation of KILLIN promoter region. In a
panel of eight RCC cell lines (RC-6, RC-9, RC-13, RC-
45, 786-O, ACHN, CAKI-1, and CAKI-2) and one nor-
mal kidney cell line HEK293T examined for KILLIN
promoter methylation, 100 % of the RCC cell lines
showed methylation in at least one of the four CpG re-
gions identified whereas HEK293T was completely
unmethylated. All the eight RCC cell lines had signifi-
cant downregulation of KILLIN expression. The use of
aza on seven of the eight RCC cell lines resulted in in-
creased expression of KILLIN in six of the seven RCC
cell lines [8].
WIF-1 gene
Wnt (Wingless type) inhibitor factor-1 is a secreted
glycoprotein antagonist that binds to Wnt protein. Wntproteins are known to have a role in cell proliferation
and oncogenesis [9]. Wnt antagonists are divided into
two classes, namely secreted frizzled-related protein
(SFRP) class and Dickkopf (Dkk) class. The SFRP family
includes the SFRP-1, SFRP-2, SFRP-3, SFRP-4, SFRP-5,
WIF-1, and Cerberus. These bind directly to Wnt and
inhibit the signaling of the Wnt pathway whereas the
Dkk family proteins bind to a component of the Wnt re-
ceptor complex to inhibit the Wnt pathway. The WIF-1
gene has been reported to have a tumor suppressor role
in various cancers. A study on the role of WIF-1 as a
tumor suppressor gene and the methylation status of its
promoter in RCC was done using Caki-2, ACHN, and
A498 RCC cell lines and a tissue microarray of 24
ccRCCs and matched normal adjacent tissues. Immuno-
staining for WIF-1 in normal specimens was signifi-
cantly (p < 0.0001) higher compared with that in ccRCC
specimens. The promoter region was found to be
densely methylated in the three RCC cell lines and
unmethylated in normal kidney samples. Treatment of
the cell lines with a demethylating agent restored the
gene expression significantly. WIF-1 transfection into
RCC cell lines significantly reduced RCC cell viability,
increased apoptotic cell fraction, and suppressed colony
formation [10].
DKK1 gene
It encodes for a protein called Dickkopf-related protein
1 which is a member of the Dickkopf family. DKK1 is a
direct inhibitor of Wnt with a role in the suppression of
human cancers. A study on the DKK1 methylation and
expression in RCC cell lines A498 and 769-P, normal
kidney cell line HK2, and RCC patient samples revealed
hypermethylation of DKK1 promoter in the RCC cell
lines and no methylation in the normal kidney cell line.
DKK1 mRNA expression was lower in A498 and 769-P
compared to that in HK2. Treatment of the RCC cell
lines with azacytidine resulted in a significant increase in
the expression of DKK1 and an increased percentage of
apoptotic cells. Immunohistochemical study on 50 ccRCC
tumor samples with corresponding 50 adjacent normal
tissues revealed significantly lower DKK1 expression in
RCC tissues. Transfection of DKK1 into RCC cells re-
sulted in growth inhibition, increased apoptosis, and
decreased invasion ability [11].
SFRP2 gene
It is a tumor suppressor gene acting as a Wnt antagonist
located at 4q31.3. Kawamoto et al. [12] studied epigenetic
mechanisms of DNA methylation and histone modifica-
tions of the silencing of SFRP2 in RCC. They examined 20
samples from newly diagnosed RCC patients who under-
went radical nephrectomy, human kidney cell line HK-2,
and RCC cell lines Caki-1, Caki-2, A-498, and ACHN. By
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strongly positive in 70 % of the normal kidney specimens
whereas majority of the RCC specimens were negative.
Using real-time quantitative reverse transcription (RT)-
PCR, they noted that SFRP2 was expressed at a signifi-
cantly higher level in HK-2 cells compared to the RCC cell
lines (A-498 and ACHN showed no SFRP2 expression
whereas Caki-1 and Caki-2 showed a low expression).
Using bisulfite genomic sequencing, it was observed that
HK-2 had no methylation of the promoter region of
SFRP2 whereas Caki-2, A-498, and ACHN cell lines dis-
played dense methylation and Caki-1 had a lower degree
of methylation compared to other RCC cell lines. Treat-
ment with DAC restored mRNA and protein expressions
of SFRP2 in all RCC cell lines.
SFRP5 gene
This gene encodes for the protein-secreted frizzled-
related protein-5(SFRP-5), a member of the SFRP family
of glycoproteins that have been identified as negative
modulators of the Wnt signal transduction pathway.
SFRP1 and SFRP2 have been shown to be epigenetically
regulated in RCC [3, 13, 14]. A study on the role of
SFRP-5 and its epigenetic regulation in RCC cell lines
Caki1, Caki2, ACHN, A498, and a tissue microarray con-
sisting of 12 ccRCCs and matched adjacent tissues re-
vealed dense methylation of SFRP-5 promoter in all
RCC cell lines and ccRCC tissue samples whereas the
same region in normal kidney tissue was mostly
unmethylated. The expression of SFRP-5 mRNA was
found to be significantly downregulated in RCC cell lines
compared to normal kidney tissue (p < 0.01). Treatment
with azacytidine restored the SFRP-5 mRNA expression
suggesting its downregulation by methylation. Transfec-
tion of A498 cells with SFRP-5 resulted in reduced an-
chorage independent colony formation efficacy, invasive
ability, and also increased apoptotic cell fraction [15].
miR-9-1 and miR-9-3 genes
The genes miR-9-1, miR-9-2, and miR-9-3 are located
on chromosomes 1, 5, and 15, respectively. These are
microRNA genes encoding hsa-miR-9, a microRNA, as
their product. MicroRNAs are small, non-coding RNAs
which control expression by targeted suppression of
gene transcription and translation. MicroRNA genes
have been shown to have a role in cancer [16, 17] and
can be epigenetically modified [18]. A study on the
methylation status of miR-9-1 and miR-9-3 in 32 pairs
of ccRCC tumor and adjacent normal tissue samples
revealed significantly higher methylation levels for both
(p = 0.00021 for miR-9-1 and p = 0.000074 for miR-9-3)
in the tumor samples compared to their adjacent normal
tissues. The methylation level was found to be nearly 2-
fold higher for miR-9-1 and over 4-fold higher for miR-9-3. They also found a significant trend of increased methy-
lation in tumor samples of higher clinical stages for both
miR-9-1 (p = 0.024) and miR-9-3 (p = 0.040). The role of
the methylation status of miR-9 genes in cases with meta-
static recurrence was then analyzed based on follow-up in-
formation of 59 ccRCC patients, of which 21 developed
metastatic recurrence. These 21 patients had a significantly
higher methylation level in their primary tumors compared
to those with no recurrence. There was significant greater-
than-30-month-reductions in recurrence-free survival
times for patients with high miR-9-1 and miR-9-3 methyla-
tion levels (p = 0.034 and p = 0.007, respectively) [19].
GREM1 gene
The gene encodes for the protein, Gremlin 1, an inhibitor
in the TGF-beta signaling pathway. GREM 1 is a secreted
glycoprotein, which is an antagonist to bone morpho-
genetic proteins (BMP) 2, 4, and 7. This antagonistic ac-
tion prevents the ligands from binding to their receptors,
thereby inhibiting downstream TGF-β signaling [20]. A
study investigating the methylation status of GREM1 pro-
moter CpG islands in four RCC cell lines—SKRC1,
SKRC10, SKRC52, and SKRC59; 150 tumor samples from
patients with sporadic ccRCC revealed heavy methylation
in the cell lines and tumor samples. There was little or no
GREM1 mRNA expression in the cell lines, and treatment
with 5′-aza-2-deoxycytidine induced mRNA expression in
all four cell lines [21].
BTG3 gene
This gene is located at chromosome 21q.21.1 and encodes
for a protein of the BTG/Tob family, a family of struc-
turally related proteins, which appear to have anti-
proliferative activity. BTG3 has been shown to be a
candidate tumor suppressor gene through its inhibitory
activity on E2F1 causing negative regulation of cell
cycle [22]. The methylation status of BTG3 in RCC was
examined using human RCC cell lines A498, ACHN,
HEK-293, normal kidney cell line HK-2, and 20 patient-
matched tumor and adjacent normal tissue paired samples.
The promoter region in RCC cell lines was completely
methylated compared to absence of methylation in HK-2
cell line. The tumor samples were hypermethylated
compared to their normal tissue samples. Real-time
quantitative PCR (qPCR) analysis for expression levels
showed relatively low levels of BTG3 expression in
tumor samples and RCC cell lines of A498, ACHN, and
HEK-293 compared to normal tissue samples and HK-2
cells. BTG3 expression was significantly increased in
RCC cell lines on treatment with 5′-aza [23].
XAF-1 gene
XIAP-associated factor-1 is a gene located at chr 17p13.1
that encodes for a protein, which is an antagonist of
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inhibit caspases which are usually active during apoptosis,
and by inhibiting these IAPs, the protein encoded by the
XAF-1 gene helps prevent uncontrolled growth in cancers.
It is an interferon (IFN)-stimulated gene inducing high
levels of XAF-1 protein in cells which are sensitive to pro-
apoptotic effects of IFN-β [24]. Pre-treatment with 5-aza-
dC has been shown to increase apoptosis induction with
IFN in RCC cell lines, ACHN, and SK-RC-45 [25]. Of the
three RCC cell lines studied—ACHN, SK-RC-45, and SK-
RC-29, ACHN had the highest increase in XAF1 expres-
sion on treatment with 5-aza-dC. Transfection of siRNA
against XAF1 was shown to reduce IFN-induced apoptosis
in cells pretreated with 5-aza-dC, confirming XAF-1 gene’s
role in apoptosis.
APAF-1 gene
The apoptotic protease activating factor-1 (APAF-1) gene
is a p53-targeted gene located at 12q23 involved in the
apoptosis regulatory network. It is involved in the activa-
tion of caspase 9 which stimulates the caspase cascade
leading to apoptosis. Inactivation of APAF-1 may result in
failure to initiate apoptosis resulting in uncontrolled cell
growth. Two studies have shown that the methylation fre-
quency of APAF-1 gene in the tumor samples is signifi-
cantly higher compared to their paired normal kidney
samples and the expression of APAF-1 is significantly
lower in the tumor samples [26, 27]. In the second study,
two RCC cell lines (A498, ClearCa-5) were treated with
sequential 5-aza-2′-deoxycytidine and significant growth
inhibition was observed from the fifth day after the initial
treatment. Also, the level of APAF-1 mRNA in the two
RCC cell lines (A498, ClearCa-5) significantly increased
after treatment with 5-aza-2′-deoxycytidine compared to
pre-treatment levels, suggesting that methylation indeed
inhibits the gene.
DAPK-1 gene
Death associated protein kinase 1 gene encodes a
calmodulin-dependent serine/threonine kinase involved in
the cell signaling pathways of survival, apoptosis, and au-
tophagy. It is a candidate tumor suppressor gene, which
acts as a mediator of IFN-γ-induced apoptosis and its loss
of expression has been linked to several tumor types. It is
reported to counteract oncogene-induced transformation
by activating a p19ARF/p53-dependent apoptotic check-
point, which is designed to eliminate pre-cancerous cells
during cancer development [28]. Christoph et al. [27] in
their study on methylation of DAPK-1 and APAF-1 and
effects of demethylating agents in kidney cancer examined
80 RCC patient samples of clear cell tumors and 20 nor-
mal kidney samples from other patients. They observed
that methylation frequency of DAPK-1 was 33 % in RCC
samples and 5 % in normal kidney samples.Nbk/Bik gene
The natural born killer gene is located at 22q13.31 and
encodes for a tissue-specific BH3-only protein with
pro-apoptotic properties. The pro-apoptotic activity
has been reported to be dependent on Bax, a member
of the Bcl-2 family [29]. In a study investigating the
link between inactivation of Nbk gene and RCC, non-
malignant renal tissue was observed to have signifi-
cantly higher protein expression of Nbk gene on immuno-
histochemistry compared to weak or absent expression of
Nbk in 57 ccRCC samples studied. Western blot analyses
showed similar results for Nbk protein expression in RCC
cell lines. RT-PCR revealed absence of Nbk mRNA in 9 of
10 RCC cell lines studied. Treatment of the cell lines with
5′-aza-2-dC resulted in increase in the expression of Nbk
mRNA and protein except in one. These results indicate
the role of Nbk as a tumor suppressor gene in RCC which
is inactivated by promoter methylation.
HOXB13 gene
The homeobox 13 gene located at chr 17q21.2 encodes a
transcription factor that belongs to the homeobox gene
family. Homeobox is a DNA sequence found within
genes that are responsible for pattern of anatomical de-
velopment. They encode for homeodomains which when
expressed as proteins can bind to DNA and switch on
cascades of other genes. HOXB13 gene has been identi-
fied to be methylated at a higher rate in primary renal
tumors [30]. Seventeen (30 %) of 56 primary RCC tumor
samples examined showed tumor-specific methylation
of HOXB13 and none in the adjacent normal kidney
tissue samples. Fifteen RCC cell lines were also studied,
and 11 (73 %) of 15 showed aberrant methylation of
HOXB13. Almost complete methylation of HOXB13
was detected in four cell lines while partial methylation
was observed in seven others The expression of
HOXB13 mRNA in the RCC cell lines was studied
using RT-PCR, and the four cell lines which showed
complete methylation revealed absence of the expres-
sion of HOXB13. Three of the four RCC cell lines were
treated with 5-aza and TSA separately, and 5-aza alone
was reported to have induced recovery of the HOXB13
expression. Transfection of KC-12 cell line with FLAG-
tagged HOXB13 was done, and the re-expression of
HOXB13 was reported to have shown significantly re-
duced number of colonies indicating its inhibitory role
in colony formation. UMRC-6 RCC cells transfected
with FLAG-HOXB13 showed increased caspase-3 activ-
ity, increased apoptotic activity with nuclear condensa-
tion, and cell death. HOXB13 methylation was also
noted to have significant correlation to tumor grade,
stage, size, and microvessel invasion. These results indi-
cate that methylation plays an important role in the
epigenetic silencing of HOXB13.
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Differentially expressed in adenocarcinoma of the lung
(DAL1) gene located at chr 18p11.32 encodes for an actin-
binding protein which has been reported to bind to tumor
suppressor in lung cancer 1 (TSLC1) protein through its
4.1-binding motif [31]. Ten of 19 (53 %) RCC cell lines ex-
amined in a study lacked DAL1 mRNA expression [32].
Nineteen surgically resected ccRCC samples with non-
cancerous renal tissues from the same patients were then
analyzed, and 12 of 19 (63 %) of the primary ccRCC sam-
ples showed absent or reduced expression of DAL1
whereas the normal kidney samples showed significant ex-
pression. The methylation status of DAL1 was assessed in
the 19 RCC cell lines of which 9 showed strong promoter
hypermethylation. These results correlated with expres-
sion studies where hypermethylation was associated with
suppressed gene expression. Caki-1, Caki-2, and KMRC-3
cell lines were treated with 5-aza-2-dC. Caki-2 and
KMRC-3 cell lines, which had hypermethylated DAL1
promoter, showed re-expression of DAL1 on treatment
whereas Caki-1 cell line, which lacked methylation, did
not show any re-expression. These results suggest a pro-
moter methylation causal role in DAL1 epigenetic silen-
cing. DAL1 promoter methylation was also found to be an
independent prognostic factor for metastatic recurrence in
ccRCC patients.
SPINT2/HAI2 gene
Serine peptidase inhibitor, Kunitz type 2 gene (SPINT2 is
also known as Bikunin), located at 19q13.1 encodes for a
transmembrane protein, which inhibits various serine pro-
teases. The SPINT2 protein inhibits hepatocyte growth
factor (HGF) activator, preventing the formation of active
HGF. Active HGF has the important role of activating
MET which in turn activates Ras/MAPK and PI3K/AKT
effector pathways that promote RCC growth and me-
tastasis [33]. Morris et al. [34] investigated the role of
epigenetic silencing of SPINT2 in RCC. Eleven RCC-
derived cell lines were subjected to treatment with 5-aza
for 5 days, and 5 of 11 (SKRC39, UMRC2, 786-O, Caki-1,
and KTCL26) had upregulation of SPINT2 expression.
Dense promoter methylation of SPINT2 was detected in
UMRC2 and SKRC39 RCC cell lines, which had shown
complete silencing of SPINT2 on RT-PCR. Thirty-four of
102 RCC samples studied and only 2 of 38 normal kidney
samples showed promoter region methylation. Transfec-
tion of SPINT2 gene in UMRC2 and SKRC39 cell lines
resulted in reduced colony formation in in vitro colony as-
says. These results suggest an important role of methyla-
tion in the silencing of SPINT2 gene in RCC.
Gamma (γ)-catenin/JUP gene
Gamma-catenin, also known as junction plakoglobin or
JUP, is a cell adhesion protein and a member of thecatenin family encoded by the gene located at chr 17q21.
It is a common constituent of desmosomes and inter-
mediate junctions, which are cell structures specialized
for cell-to-cell adhesion. Loss of function of cell adhesion
proteins like gamma-catenin has been reported to disrupt
intercellular interaction between tumor cells correlating
with poorer prognosis in cancers [35]. The adverse effect
on prognosis of silencing γ-catenin gene expression has
been reported in thyroid and lung cancers [36, 37]. The
role of DNA methylation as a mechanism of silencing the
γ-catenin gene in RCC was investigated in a study with 54
patient samples of primary RCC and matched normal
kidney samples and 3 RCC cell lines A498, Caki-1, and
Caki-2. The study revealed strong expression in normal
kidney samples and weak expression in the majority of
RCC tissues. The levels of mRNA transcripts were also
significantly lower in RCC samples compared to normal
kidney samples (p < 0.05). Treatment with 5-aza-dC of
the three RCC cell lines (A498, Caki-1 and Caki-2)
showed increased levels of γ-catenin mRNA expression
after treatment compared to untreated controls.
TCF 21 gene
Transcription factor 21 (TCF21) has been identified as a
candidate tumor suppressor at 6q23-q24 that is epige-
netically inactivated in many cancers [38]. The methyla-
tion status of TCF21 has been found to be very high in
clear cell RCC samples compared to normal adjacent tis-
sue samples. Treatment with DNA demethylating agent
5′-azacytidine restored part of the TCF21 expression in
786-O cell lines [39]. In another study, a significant in-
verse correlation was found between TCF21 methylation
and expression levels in untreated renal cancer cell lines.
Treatment with 1 μM or 5 μM 5-aza-dC resulted in in-
creased expression of the gene [40].
PCDH17 gene
PCDH17 encodes a protocadherin which is believed to
have tumor-suppressing functions due to its cell adhe-
sion, signal transduction, and growth control functions
even though its exact mechanism has not been clearly
defined. PCDH17 promoter region was found to be
hypermethylated in 48 % of BlCa, 61 % of RCT, and
60 % of Pca samples [40].
HIC1 gene
This gene encodes the hypermethylated-in-cancer 1
protein which functions as a transcriptional repressor.
The gene has been shown to participate in complex
regulatory loops regulating p53 and E2 transcription
and factor 1 (E2F1) DNA damage responses [41–43].
Loss of HIC1 function has been associated with occur-
rence of various tumors. A study on the role of CpG island
methylation of HIC1 in RCC using bisulfite conversion
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tissue specimens identified HIC1 hypermethylation in tu-
mors as an independent predictor of reduced recurrence-
free survival [44].
LRRC3B gene
Leucine-rich repeat-containing 3B (LRRC3B) is an evolu-
tionarily, highly conserved leucine-rich repeat-containing
protein, but its biological significance is largely unknown.
It was suggested that human genome has more than 2000
LRR-containing proteins and they participate in many
important processes, including plant and animal im-
munity, hormone–receptor interactions, cell adhesion,
signal transduction, regulation of gene expression, and
apoptosis. A number of microarray expression profiling
studies have shown that LRRC3B is downregulated in
various cancers suggesting that LRRC3B is involved in
carcinogenesis [45]. In a study on its role in RCC, 57 %
of the renal cancer samples studied showed hypermethyla-
tion and/or deletion. Expression analysis of LRRC3B using
RT-qPCR revealed that it was almost unchanged in stages
I and II of RCC but decreased 2- to 6-fold in stage III.
The gene was also shown to exhibit strong cell growth
inhibiting activity in colony formation experiments
in vitro, further suggesting its role as a tumor suppres-
sor gene [46].
GATA5 gene
GATA5 belongs to a family of zinc-finger transcription
factors (GATA1–6) showing high affinity to the consen-
sus DNA sequence (A/T)GATA(A/G) [47] and is a
tumor suppressor gene downregulated in various can-
cers. A study on the CGI methylation level of GATA5
gene in RCC cell lines RCC-GS, 786-O, A498, ACHN,
RCC-HS, as well as primary renal proximal tubular epi-
thelial cells (RPTEC) using combined bisulphite restric-
tion analysis (COBRA) revealed that the methylation
level was 77 % in 786-O, 53 % in RCC-GS, 89 % in
RCC-HS, 99 % in RCC-MF, 99 % in A498, 12 % in
ACHN, and 2 % in RPTEC. Increased GATA5 CGI
methylation in the ccRCC group correlated with metas-
tasis (p = 0.005) and decreased progression-free survival
(p = 0.005) [48].
RASSF1 gene
It encodes for the protein Ras-association-domain-con-
taining protein 1 and is a tumor suppressor gene located
at 3p21. The RASSF1 gene has several major isoforms
because of alternative splicing and promoter usage, but
epigenetic silencing of the longer isoform, RASSF1A, is
specifically associated with cancer [49].
RASSF1A is functionally involved in cell-cycle control,
microtubule stabilization, cellular adhesion, motility, as
well as apoptosis [50]. In one study, the median normalizedindex of methylation of RASSF1A promoter was signifi-
cantly higher in papillary RCC samples compared to their
normal adjacent tissue samples (2.11 vs 0.61, p < 0.001)
[51]. Another study assessed the relation between methyla-
tion levels of RASSF1A and prognosis in 179 patients who
underwent radical or partial nephrectomy for ccRCC. The
level of methylation of RASSF1A promoter was found to
be more in patients with stage III or IV RCC compared to
patients with stage I or II (p = 0.043). Higher methylation
level was independently associated with a poor prognosis
following multivariate analysis (p = 0.0053) [52]. In another
study, RASSF1A was observed to have significantly higher
percentage of methylation in papillary RCC compared to
other types of RCC [53].
UNC5C gene
The gene product UNC5C belongs to the UNC5H func-
tional dependence receptor family, acts as one of the
Netrin-1 receptors and has the ability to induce apop-
tosis in the absence of the Netrin-1 ligand [54, 55].
UNC5C is expressed in the proximal tubule of the kid-
ney where most of the RCCs originate [56]. RT-PCR
study of five RCC cell lines 786-O, Os-RC-2, A498,
ACHN, and Caki-1 revealed weak expression of UNC5C
in Caki-1 cell line and undetectably low expression in
the other four. Two out of five RCC cell lines—786-O
and Os-RC2, were found to have hypermethylated
UNC5C. Treatment of the two cell lines with DNA de-
methylation agent aza resulted in a significant increase
in the expression of UNC5C. Forty-four primary RCC
samples paired with their normal adjacent tissues were
then studied, and all RCC samples were found to have
downregulated UNC5C expression compared to their
adjacent normal tissues. Of the 44, 12 showed hyperme-
thylation of UNC5C promoter (27.3 %) in comparison to
no methylation in their corresponding normal tissues.
KRT19
KRT19 gene located at 17q21.2, encodes for the protein
cytokeratin (CK) 19 [57]. It is a potential tumor suppres-
sor that negatively regulates Akt signaling [58]. In nor-
mal kidney tissue, CK19 is expressed by distal tubules
and collecting duct cells. A study was conducted on
RCC cell lines 769-P, 786-O, Caki-1, Caki-2, A498, and
ACHN and 112 RCC patient samples for methylation
and expression levels of KRT19. The promoter methyla-
tion and mRNA relative expression levels showed a sta-
tistically significant (p < 0.001) inverse relation in 769-P,
Caki-1, Caki-2, A498, and ACHN. The RCC cell line
786-O showed low levels of both methylation and ex-
pression. Treatment with 5 μm azacytidine of four RCC
cell lines—769-P, Caki-1, Caki-2, and A498, was done
(786-O and ACHN had low levels of methylation and
were therefore excluded) and except for Caki-2, KRT19
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creased mRNA expression. Caki-2 had the lowest
methylation levels among the four cell lines to start with.
In the tissue samples, 23 out of 112 (9/52 ccRCC, 6/22
pRCC, 2/22 chrRCC, 6/16 oncocytoma) showed hyper-
methylation of KRT19 [59].
GATA3 gene
Trans-acting T cell-specific transcription factor GATA-3 is
a protein encoded by this gene. GATA3 protein has a role
in regulating Th2 development and function and is select-
ively expressed during human kidney embryogenesis [60].
It regulates the expression of TβRIII (a receptor for TGF-
β signaling pathway that contributes to inhibition of cell
proliferation) by acting on the proximal promoter region
of the TβRIII gene. GATA3 expression has been shown to
be downregulated in all stages of ccRCC in two studies
[61, 62], and reduced expression of GATA3 results in con-
comitant downregulation of TβRIII protein expression.
GATA3 gene promoter has been found to be strongly
methylated in tumor samples and treatment of an RCC
cell line, and UMRC2 with 5′-aza resulted in dramatic in-
crease in GATA 3 mRNA expression [61].
TIMP3 gene
Tissue inhibitor of metalloproteinase 3 is a member of
endogenous matrix metalloproteinase (MMP) inhibitors
[63] and is a physiological antagonist for VEGFR-2.
VEGF signaling is highly enhanced in most ccRCC tu-
mors. A study on 105 patients who underwent radical or
partial nephrectomy for ccRCC revealed that, compared
to the normal renal tissue, 100 out of 105 of them had
reduced TIMP3 expression [64]. Another study reported
that 4 out of 12 (33 %) RCC cell lines, 28 out of 36
(78 %) tumor samples, and 0 out of 27 normal tissue
samples studied had hypermethylation of TIMP3 gene
promoter. The methylation was found to be similar in
all grades of renal cell carcinomas suggesting that this
epigenetic change might occur during early stages of
cancer [65].
TU3A gene
TU3A is a candidate tumor suppressor gene located in
chromosome 3p21.1. The role of methylation in silen-
cing of TU3A expression in human cancers like renal,
bladder, cervical, breast, hepatic, ovarian, and testicular
cancer cells was studied by Awakura et al. They exam-
ined the RCC cell lines of Caki-1, ACHN, and NC65 and
found that ACHN had low expression of TU3A while
the other two did not show any expression. The treat-
ment with 5′-aza restored the expression of TU3A
mRNA expression in all the three cell lines, and expression
was even more prominent when 5′aza and Trichostatin A
(histone deacetylase inhibitor) were used in combination.They also found the hypermethylation of TU3A promoter
to be significantly associated with advanced tumor stage
and poor disease-specific survival [66].
FHIT gene
Fragile histidine triad protein (FHIT) is an enzyme that is
encoded by the FHIT gene located at 3p14.2. The gene is
reported to act as a tumor suppressor gene by growth in-
hibition and apoptosis induction in various cancers. The
role of DNA promoter hypermethylation in the expression
of FHIT in clear cell RCC was studied by Kvasha et al. [67]
They conducted methylation-specific PCR for 22 paired
clear cell renal cell carcinoma and non-malignant renal tis-
sues and observed hypermethylation in 12 of 22 (54.5 %) of
the ccRCC samples and almost none in the non-malignant
tissues. They also noted that frequency of hypermethyla-
tion was significantly higher in patients older than 50 years
than in patients younger than 50 (p = 0.027). They
observed significantly decreased expression of FHIT in
tumor samples with methylated FHIT gene using
semi-quantitative RT-PCR whereas the unmethylated
samples showed FHIT expression at high levels.
DLK1 gene
The delta-like 1 homolog gene located at chr 14q32 is an
imprinted gene that is paternally expressed and encodes
for a transmembrane protein involved in differentiation of
several cell types including adipocytes. Kawakami et al.
[68] noted the common deletion at 14q32 in RCCs and
hypothesized DLK1 involvement in RCC tumorigenesis.
Fifteen RCC cell lines and a series of 50 cases of surgically
resected primary RCC tissues (clear cell, non-papillary
RCCs) and their adjacent normal kidney tissues were used
in this study. They noted loss of expression of DLK1 in 39
out of 50 (78 %) primary RCC tissues whereas expression
of DLK1 was maintained in every normal kidney tissue.
Only 1 (NC65) of 15 RCC cell lines was noted to have
expression. Using immunohistochemical analysis of
DLK1 protein, they reported that it was most expressed
in the renal tubular cells, which is the site of origin of
RCCs. Transfection of DLK-1 resulted in increased
apoptosis in all four transfected RCC cell lines com-
pared to controls. A significant decrease in subcutane-
ous tumor growth in nude mice was observed after
restoration of DLK1 in comparison to control cell lines
suggesting tumor suppressive activity of DLK1 both
in vitro and in vivo. DLK1 and GLT2 were previously
reported to be reciprocally imprinted genes [69], and it
was further confirmed in this study. The methylation of
the CpG2 island of GLT2 gene was found to corres-
pond with the expression of DLK1 gene. Treatment
with 5′aza resulted in the recovery of DLK1 expression
associated with demethylation of CpG2 region of GLT2
in cell lines.
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The Cx32 gene located at chr Xq13.1 encodes for a gap
junction protein, which forms a part of gap junction
channels that facilitate the transfer of ions and small
molecules between cells. Patients undergoing long-term
hemodialysis have the risk of developing acquired cystic
kidney disease (ACKD), and these cysts develop from
the progenitor cell of RCC, the proximal tubular cell.
RCC tends to arise from the papillary adenomas that
tend to arise from the cysts of ACKD. Connexin 32 has
been reported to have a tumor-suppressive role against
renal cell carcinoma in hemodialysis patients [70, 71]. In
a study investigating the methylation status of Cx32
promoter and its role as tumor suppressor gene in RCC
occurring in hemodialysis patients, 19 tumors and 19
matched non-cancerous tissues of kidneys from
hemodialysis patients along with 10 matched pairs of RCC
tumors and normal tissues from general patients who did
not have any hemodialysis were studied. It was observed
that 15 of 19 non-cancerous tissues from the hemodialysis
patients were methylated and all of the 10 normal tissues
of kidneys from the general patients were unmethylated
which was a significant difference (p = 0.0001). The
methylation status correlated with the expression of the
gene. The mean duration of hemodialysis in patients with
positive methylation status was 51.2 months whereas it
was 33.6 months in patients with negative methylation
status for Cx32. It was suggested that longer duration
of hemodialysis induces methylation of Cx32.
ECAD gene
ECAD, also known as E Cadherin or CDH1 or Cadherin
1 located at 16q22.1 is from the cadherin superfamily.
The gene encodes for a calcium-dependent cell-cell ad-
hesion glycoprotein. Loss of the gene function has been
studied in various cancers and is thought to contribute
to the progression of cancer in the later stages by in-
creased proliferation, invasion, and/or metastasis. A
good correlation has been observed between ECAD gene
promoter methylation and tumor grade with grade 3
RCC tumors having 100 % methylation, grade 2 having
57 %, and grade 1 having 57 % methylation [72]. In the
same study, four RCC cell lines 769-P, 786-O, Caki-1,
and Caki-2 were reported to have a higher degree of
methylation at most of the CpG sites of the ECAD pro-
moter region compared to normal kidney cells which
did not have any methylation. Treatment with 5-aza for
3 days resulted in increased ECAD mRNA expression in
all four RCC cell lines.
HOXA5
Homeobox A5 is a part of the homeobox genes found in
cluster, named as A, B, C, and D on four separate chromo-
somes. This gene is part of the A cluster on chromosome7 and codes for a DNA-binding transcription factor which
controls gene expression, morphogenesis, and differenti-
ation. The protein upregulates p53, a tumor suppressor
gene, and its epigenetic silencing by methylation can thus
play a significant role in tumorigenesis. A study on 62
clear cell RCC cases with paired tumor and normal adja-
cent tissue revealed that the methylation status of HOXA5
had a significant relationship with Fuhrman’s nuclear
grade (p = 0.041). The high methylation status group had
high Fuhrman’s nuclear grade. The HOXA5 gene had a
methylation rate of 51.6 % in cancer tissue and 21 % in
normal tissue. However, there was no significant relation-
ship between the HOXA5 methylation status and patient
survival [73].
MSH2
It is located on chromosome 2 and encodes for DNA
mismatch repair protein Msh2. Msh2 protein is involved
in many different forms of DNA repair, including tran-
scription coupled repair, homologous recombination,
and base excision repair. Yoo et al. [73] identified MSH2
along with HOXA5 as a hypermethylated gene. At
MSH2, the methylation rate was 54.8 % in cancer tissue
and 26.1 % in normal tissue. There was no statistically
significant relationship between the MSH2 methylation
status and patient survival, similar to HOXA5. Further
studies with demethylating drugs on RCC samples and
cell lines could be done to identify the role of epigenetic
silencing on MSH2.
VHL gene
Von Hippel-Lindau tumor suppressor gene inactivation
by promoter region hypermethylation was first reported
in 1998. The VHL promoter region was reported to be
hypermethylated in 11 % of the primary RCCs (11/99),
and 10 of these tumors showed no evidence of concomi-
tant VHL gene mutation suggesting that the two were
mutually exclusive [74]. Similarly, epigenetic silencing of
VHL gene was reported in 7 % of clear cell RCC tumors
by the Cancer Genome Atlas Research Network group
in 2013 [75].
UQCRH gene
UQCRH is a tumor suppressor gene encoding a mito-
chondrial hinge protein. It was found to be hyper-
methylated and suppressed in 36 % of the clear cell
RCC tumors by the Cancer Atlas Research Network
group [75].
DACH1
It is a tumor suppressor that inhibits cyclin D1 expres-
sion and is known to be suppressed in RCC by hyperme-
thylation. Treatment with decitabine has been shown to
restore the expression of DACH1 [76].
Table 1 List of genes known to be modified by the methylation status in renal cell cancer (references in the text)
Gene Function Promoter methylation
in renal cancer tissue
compared to normal
tissue




agent on gene expression
TCF-21 Tumor suppressor gene involved in
specification of differentiation
↑↑ ↓ ↑
PCDH17 Tumor suppressor gene involved in
calcium-dependent cell adhesion
↑↑ ↓ ?
LRRC3B Tumor suppressor gene involved in cell
adhesion and apoptosis
↑↑ ↓ ?
SFRP1 Wnt antagonist tumor suppressor ↑↑↑ ↓↓ ?
RAP1GAP Tumor suppressor (inactivates Rap-
mediated invasion and metastasis)
↑↑ ↓ ↑
RASSF1 Tumor suppressor (cell-cycle control,
microtubule stabilization)
↑↑↑ ↓↓ ↑↑
UNC5C Tumor suppressor (induction of apoptosis) ↑↑ ↓↓ ↑↑
KILLIN Tumor suppressor (cell-cycle arrest,
regulated by p53)
↑↑↑ ↓↓ ↑↑
KRT19 Organization of myofibrils and maintaining
structural integrity of epithelial cells
↑↑ ↓↓ ↑↑
HOXA5 Tumor suppressor (upregulates p53) ↑ ? ?
MSH-2 DNA mismatch repair ↑ ↓ ↑
miR-9-1 and miR-9-3 Targeted suppression of gene transcription
and translation
↑ ↓ ?










GATA-3 TBRIII signaling. inihibitor of cell
proliferation
↑↑↑ ↓↓ ↑↑
TIMP-3 VEGF-3 antagonist, matrix
metalloproteinase inhibitor
↑↑ ↓↓ ?
GREM-1 gene TGF-β signaling inhibition ↑↑ ↓↓ ↑↑





UCHL1 Ubiquitination of proteins ↑↑ ↓ ↑
BTG3 E2F1 inhibition → negative regulation of
cell cycle
↑↑↑ ↓↓ ↑↑
TU3A Tumor suppressor, mechanism unknown ↑↑ ↓ ↑
14-3-3 sigma Causes G2 phase block for DNA repair ↑ ↓ ↑
p16 Cyclin kinase-dependent inhibition →
causes cell-cycle arrest
↑ ↓ ?
SFRP2 Wnt antagonist ↑↑↑ ↓↓ ↑↑
FHIT Tumor suppressor, induction of apoptosis ↑↑ ↓↓ ?
XAF-1 Pro-apoptotic gene, inhibitor of “inhibition
of apoptosis” protein
↑↑ ↓ ↑
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Table 1 List of genes known to be modified by the methylation status in renal cell cancer (references in the text) (Continued)
APAF 1 Pro-apoptotic gene, activation of caspase 9 ↑↑↑↑ ↓↓↓ ↑↑
DAPK-1 Mediation of IFN-γ induced apoptosis ↑ ↓ ?
DLC-1 Inhibitor of RhoAGTPase ↑ ↓ ?
DLK-1 Pro-apoptotic gene ↑↑ ↓↓ ↑↑ (Transfection decreases
cell proliferation,
increases cell apoptosis)
HOX-B-13 Pro-apoptotic gene ↑↑↑ ↓↓ ↑↑ (Transfection decreases
cell proliferation)
DAL-1 Protein 4.1-related tumor suppressor gene ↑↑ ↓ ↑
SPINT-2 Tumor suppressor: inhibits HGF which
activates Ras pathway
↑↑ ↓ ? (Transfection decreases
cell proliferation)
Gamma-catenin Involved in cell-cell adhesion. Loss of
function correlates with poorer prognosis
in cancer
↑↑↑ ↓↓ ↑↑
Connexin-32 Gap junction protein. May be involved in
the increased incidence of RCC in
maintenance hemodialysis patients
↑↑ ↓↓ ?
Ecad Tumor suppressor: encodes for cell-cell
adhesion glycoprotein
↑↑ ↓↓ ↑↑
HLA-G Tumor promoter: involved in helping
tumor cells evade immunosurveillance
? ↑ ↑





CA9/G250 Tumor promoter: expressed in hypoxic
tumors, produces bicarbonate which
neutralizes the surrounding acidic pH and
aids cancer progression
↓↓ ↑↑ ↑
CYTIP Promotes metastasis. Helps tumor cells
evade cell death cytokines
↑↑ ? ↑
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tioned tumor suppressor genes in RCC, hypomethylating
agents may also increase the expression of a few (four
known) tumor promoter genes, namely Interleukin-8,
which promotes angiogenesis and metastasis [77]; HLA-G,
which is known to help tumor cells evade immunosurveil-
lance [78]; G250, which produces bicarbonate and neutral-
izes the surrounding acidic pH and aids cancer progression
[79]; and CYTIP, which helps tumor cells evade cell death
cytokines [80]. However, the overall effect of hypo-
methylating agents is that of tumor suppression, as a
result of increased expression of a much higher number
of tumor suppressor genes compared to tumor promoter
genes. Hypomethylating agents have been shown to inhibit
RCC cell proliferation both in vitro and in xenograft
studies [81, 82] (Table 1).
Genome-wide studies reveal novel epigenomic
alterations in RCC that affect regulatory regions
of the genome
Even though recent studies have shown that epigenetic
changes at enhancers can influence carcinogenesis, mostmethylomic studies in RCC detailed above focused on
changes at promoters and were single locus studies. We
studied genome-wide patterns of DNA methylation in
ccRCC at a high resolution analysis of 1.3 million CpGs
with the HELP assay. Microdissected renal tubular cells
were used as controls. We observed that the RCC sam-
ples were characterized by aberrant hypermethylation
that preferentially affected gene bodies. The hyperme-
thylation was particularly enriched in kidney-specific en-
hancer regions associated with H3K4Me1 marks. This
genome-wide hypermethylation in ccRCC is in contrast
to other solid tumors such as esophageal cancer, hepato-
cellular cancer, head and neck cancers, etc., that are
characterized by genome-wide hypomethylation. MOTIF
analysis of aberrantly hypermethylated regions revealed
enrichment for binding sites of AP2a, AHR, HAIRY,
ARNT, and HIF1 transcription factors, reflecting possible
contributions of dysregulated hypoxia signaling pathways
to epigenetic changes in RCC. The functional importance
of this aberrant hypermethylation was demonstrated
by selective sensitivity of RCC cells to low levels of
DNA methyltransferase inhibitors. Most importantly,
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prognosis in a large cohort of ccRCC samples [83].
The Cancer Genome Atlas Research Network group
also reported that increasing promoter hypermethylation
frequency correlated with higher stage and grade in clear
cell RCC [75]. Apart from discovering hypermethylation
of VHL and UQCRH tumor suppressor genes in some
ccRCC samples (as described above), they also made an
interesting evaluation of the global consequence of mu-
tations in specific epigenetic modifiers. Inactivating mu-
tations of the SetD2 gene occur in a few cases of ccRCC
and was found to be associated with increased loss of
DNA methylation. SetD2 is a H3K36 methyltransferase.
H3K36 trimethylation has been suggested to be involved
in the maintenance of the heterochromatin state. DNA
methyltransferase 3A (DNMT3A) binds to trimethylated
H3K36 and methylates nearby DNA resulting in tran-
scriptional silencing. Consequently, it was thought that
reduction in trimethylated H3K36 levels through SetD2
inactivation could lead to regional loss of DNA methyla-
tion [75]. It would be interesting to study the effect of
hypomethylating agents in SetD2 mutant and wild-type
ccRCC to determine if inactivating mutations of SetD2
can be indicators of poor response to hypomethylating
agents.
Conclusions
DNA methylation plays an important role in the develop-
ment and progression of renal cell carcinoma. Epigenetic
silencing of numerous tumor suppressor genes caused by
hypermethylation of enhancer and promoter CpGs leads to
increased tumor cell proliferation, invasion, and metastasis.
In particular, activation of Wnt pathway by suppression of
Wnt antagonists, namely SFRP1, SFRP2, SFRP5, and WIF-
1 appears to play a very prominent role in the proliferation
of many RCC cell lines and patient tumor samples—as de-
termined by a higher percentage of methylation in cancer
tissue compared to normal tissue, very low expression
compared to normal tissue, significant inhibition of prolif-
eration, and increase in apoptosis caused by transfection of
the Wnt antagonist genes. Similarly, TGF-β pathway
activation by promoter methylation-induced inhibition
of pathway inhibitory genes GATA-3, GREM-1, and
SMAD-6 plays a significant role in many RCC cell
lines. Silencing of pro-apoptotic genes such as APAF-1
and negative regulators of cell cycle such as KILLIN
and RASSF1 also appear to play an important role.
Hypomethylating agents have shown inhibition of
renal carcinoma cell proliferation both in vitro and in
xenograft studies by the re-expression of numerous
tumor suppressor genes silenced by enhancer/promoter
hypermethylation [81, 82]. Despite the possibility of sim-
ultaneous increased expression of some tumor promoter
genes, the overall effect of hypomethylating agents onRCC is that of tumor suppression due to increased ex-
pression of a much higher number of tumor suppressor
genes. The genome-wide hypermethylation in RCC is in
contrast to other solid tumors which demonstrate wide-
spread hypomethylation, thereby making hypomethylat-
ing agents and other epigenetic modulators potential
therapeutic agents in RCC, along with emerging targeted
therapies [84–86].
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